TY - JOUR
T1 - In heart failure, all beta-blockers are not necessarily equal
AU - Tang, W. H.Wilson
AU - Militello, Michael
AU - Francis, Gary S.
PY - 2003/12
Y1 - 2003/12
N2 - The Carvedilol or Metoprolol European Trial (COMET; Lancet 2003; 362:7-13) found that in patients with heart failure, survival appears to be better with carvedilol than with immediate-release metoprolol tartrate. Whether the target doses used were equivalent (carvedilol 25 mg twice daily vs metoprolol tartrate 50 mg twice daily) has been debated, but the COMET trial shows that drugs in the same class do not necessarily have the same effects. Given the overwhelming evidence of the benefit of carvedilol, metoprolol succinate, and bisoprolol in patients with heart failure, we should all strive to increase the use of these drugs in appropriate doses.
AB - The Carvedilol or Metoprolol European Trial (COMET; Lancet 2003; 362:7-13) found that in patients with heart failure, survival appears to be better with carvedilol than with immediate-release metoprolol tartrate. Whether the target doses used were equivalent (carvedilol 25 mg twice daily vs metoprolol tartrate 50 mg twice daily) has been debated, but the COMET trial shows that drugs in the same class do not necessarily have the same effects. Given the overwhelming evidence of the benefit of carvedilol, metoprolol succinate, and bisoprolol in patients with heart failure, we should all strive to increase the use of these drugs in appropriate doses.
UR - http://www.scopus.com/inward/record.url?scp=0346102796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0346102796&partnerID=8YFLogxK
U2 - 10.3949/ccjm.70.12.1081
DO - 10.3949/ccjm.70.12.1081
M3 - Article
C2 - 14686687
AN - SCOPUS:0346102796
VL - 70
SP - 1081
EP - 1087
JO - Cleveland Clinic Journal of Medicine
JF - Cleveland Clinic Journal of Medicine
SN - 0891-1150
IS - 12
ER -